Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Sundahl, Nora; De Meerleer, Gert; Villeirs, Geert; Ost, Piet; De Neve, Wilfried; Lumen, Nicolaas; De Visschere, Pieter; Van Eijkeren, Marc; Fonteyne, Valérie
• Is Part Of: Radiotherapy and oncology. Volume 119:Issue 3(2016:Jun.)
• Page Start: 398
• Page End: 404
• Publication Date: 2016-06
• Subjects: Toxicity -- Prostate cancer -- Intraprostatic lesion -- Dose escalation; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2016.04.031
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: Local recurrences after radiotherapy are dose-dependent and occur in the dominant intraprostatic lesion (DIL). The purpose of this study was to evaluate the impact of a simultaneous integrated boost (SIB) to the magnetic resonance imaging (MRI)-defined DIL on toxicity. Materials and methods: Four-hundred and ten patients were treated with intensity-modulated radiotherapy. A median dose of 78 Gy was prescribed to the prostate. A SIB of 82 Gy to the DIL was performed in 225 patients (SIB+). Genitourinary and rectal toxicity on fixed time points up to 8 years were compared between SIB− (185 patients) and SIB+ patients. Chi-square, Fisher's exact and Kaplan–Meier statistics were applied. With a median follow up of 72 months, the six-year actuarial risk of genitourinary and rectal toxicity grade ⩾ 2 was 31% and 12% respectively. The actuarial risk of developing toxicity and incidence of symptoms at fixed time points were not increased with a SIB. Conclusion: Performing a SIB did not increase genitourinary or rectal toxicity up to 8 years' follow-up.